|
Variables
|
HR (95% CIa)
|
P-value
|
|---|
|
EP
|
1.126 (1.041 to 1.219)
|
0.0031
|
|
Number Positive Nodes
| |
<0.0001b
|
|
1 to 3
|
Reference value
| |
|
4 to 10
|
1.420 (0.932 to 2.166)
|
0.1030
|
|
>10
|
3.605 (2.102 to 6.185)
|
<0.0001
|
|
Age
|
0.983 (0.966 to 1.001)
|
0.0628
|
|
Tumor size
| |
0.6631b
|
|
≤1 cm
|
Reference value
| |
|
>1 to ≤2 cm
|
0.789 (0.343 to 1.816)
|
0.5774
|
|
>2 to ≤5 cm
|
1.042 (0.466 to 2.331)
|
0.9196
|
|
>5 cm
|
0.880 (0.301 to 2.577)
|
0.8159
|
|
Treatment arm
| |
0.9331b
|
|
FEC
|
Reference value
| |
|
FEC-P
|
1.016 (0.697 to 1.482)
| |
|
Grade
| |
0.4650b
|
|
G1
|
Reference value
| |
|
G2
|
1.662 (0.830 to 3.329)
|
0.1519
|
|
G3
|
1.589 (0.747 to 3.377)
|
0.2290
|
|
Unknown
|
1.198 (0.470 to 3.052)
|
0.7051
|
|
ER (Allred score
c
)
|
0.980 (0.903 to 1.063)
|
0.6207
|
|
PR (Allred score
c
)
|
0.965 (0.902 to 1.032)
|
0.2947
|
|
Ki67 quantitative
|
1.001 (0.986 to 1.016)
|
0.8982
|
- aCI: Confidence interval; EP: EndoPredict; EPclin: Combined molecular and clinical score; ER: Estrogen receptor; HR: Hazard ratio; MFS: Metastasis-free survival; PR: Progesterone receptor. bP-value of the variable’s overall effect on MFS. cAllred et al. [18]. Multivariate analyses included 534 patients and 116 events.
